Merck & Co., Inc. (MRK)
NYSE: MRK · Real-Time Price · USD
96.24
-1.68 (-1.72%)
Jan 21, 2025, 4:01 PM EST - Market closed
Merck & Co. Revenue
Merck & Co. had revenue of $16.66B in the quarter ending September 30, 2024, with 4.35% growth. This brings the company's revenue in the last twelve months to $63.17B, up 6.51% year-over-year. In the year 2023, Merck & Co. had annual revenue of $60.12B with 1.40% growth.
Revenue (ttm)
$63.17B
Revenue Growth
+6.51%
P/S Ratio
3.86
Revenue / Employee
$877,417
Employees
72,000
Market Cap
243.45B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 60.12B | 832.00M | 1.40% |
Dec 31, 2022 | 59.28B | 10.58B | 21.72% |
Dec 31, 2021 | 48.70B | 7.19B | 17.31% |
Dec 31, 2020 | 41.52B | 2.40B | 6.13% |
Dec 31, 2019 | 39.12B | -3.17B | -7.50% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 87.70B |
AbbVie | 55.53B |
AstraZeneca | 51.21B |
Novartis AG | 49.94B |
Thermo Fisher Scientific | 42.37B |
Abbott Laboratories | 41.22B |
Eli Lilly and Company | 40.86B |
MRK News
- 1 day ago - Merck: 3x Pipeline And Undervaluation Make It A Buy - Seeking Alpha
- 1 day ago - High-Quality Dividend Growth Stocks Near 52-Week Lows: Merck Is Magnificent - Seeking Alpha
- 3 days ago - Exclusive: Kennedy played key role in vaccine case against Merck - Reuters
- 4 days ago - What's In Store For Merck Stock In 2025? - Forbes
- 5 days ago - Merck to Hold Fourth-Quarter and Full-Year 2024 Sales and Earnings Conference Call Feb. 4 - Business Wire
- 7 days ago - Jim Cramer says he supports healthcare stocks for their long-term value - CNBC
- 7 days ago - Merck CEO talks medicines beyond the company's top cancer drug - CNBC
- 7 days ago - Merck & Co. Inc. (MRK) 43rd Annual J.P. Morgan Healthcare Conference (Transcript) - Seeking Alpha